Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
22. März 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended...
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
02. März 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
09. Februar 2023 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
19. Dezember 2022 07:37 ET
|
Wave Life Sciences USA, Inc.
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compared with Wave’s first-generation...
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
13. Dezember 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties Collaboration brings together Wave’s PRISM™ oligonucleotide platform and...
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
10. November 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in...
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
09. November 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
03. November 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
03. Oktober 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
Six presentations and posters between OTS and ESGCT meetings will highlight Wave’s oligonucleotide chemistry advancements as well as RNA editing and RNAi capabilities First presentation in a...
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event
28. September 2022 13:30 ET
|
Wave Life Sciences USA, Inc.
WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver...